You are hereBiblio / How Much Is More Life Worth?
How Much Is More Life Worth?
| Title | How Much Is More Life Worth? |
| Publication Type | Journal Article |
| Year of Publication | 2006 |
| Authors | Brock, Dan W. |
| Journal | Hastings Center Report |
| Volume | 36 |
| Issue | 3 |
| Pagination | 17-19 |
| Publisher | Hastings Center |
| Type of Article | Editorial |
| Publication Language | eng |
| ISSN Number | 00930334 |
| Keywords | ANTINEOPLASTIC , Drugs , ethics , GENENTECH , Pharmaceutical , PRICE |
| Abstract | Comments on ethical issues raised by the justification offered by Genentech Inc. for the drug price increase. Reason commonly cited by pharmaceutical companies for drug price increases; Factors considered by Genentech Inc. in pricing its Avastin drug for cancer; Cost-effectiveness of Avastin using quality-adjusted life years threshold. |
| Notes | 3Accession Number: 20826341; Brock, Dan W.; Source Info: May/Jun2006, Vol. 36 Issue 3, p17; Subject Term: ETHICS; Subject Term: DRUGS -- Prices; Subject Term: PRICE increases; Subject Term: ANTINEOPLASTIC agents; Subject Term: PHARMACEUTICAL industry; Company/Entity: GENENTECH Inc. Ticker: DNA; NAICS/Industry Codes: 325412 Pharmaceutical Preparation Manufacturing; Number of Pages: 3p; Document Type: Editorial |
| DOI | 10.1353/hcr.2006.0036 |
